New treatment options with cytotoxic agents in neuroendocrine tumours View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-08-22

AUTHORS

Pascal Hammel, Olivia Hentic, Cindy Neuzillet, Sandrine Faivre, Eric Raymond, Philippe Ruszniewski

ABSTRACT

There are numerous treatment options for patients with advanced digestive neuroendocrine tumours (NETs). Medical treatment includes systemic chemotherapies, targeted therapies, somatostatin analogs, liver-directed therapies such as (chemo)embolization or thermoablation, and peptide receptor radionuclide therapy. Cytotoxic chemotherapies can help control tumour progression in patients with non-resectable tumours and may improve symptoms by reducing tumour bulk. In addition, tumour response is usually greater than that obtained with targeted therapies. This should be taken into consideration in neoadjuvant strategies. Efficacy of temozolomide depends on the O6 methylguanine DNA methyl transferase status, and thus, this drug will likely have to be considered in the future in patients with a favourable enzyme profile. Because numerous treatment options are available for patients with advanced digestive NETs, and thanks to their long survival, successive drugs should be used. Careful attention should be paid to the adverse events in order to maintain the quality of life in these patients who have with a long life expectancy. More... »

PAGES

169-172

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-012-0228-7

DOI

http://dx.doi.org/10.1007/s11523-012-0228-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1047764482

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22911013


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibiotics, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Alkylating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoid Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytotoxins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Modification Methylases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Repair Enzymes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dacarbazine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medical Oncology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuroendocrine Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Streptozocin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Temozolomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Suppressor Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hammel", 
        "givenName": "Pascal", 
        "id": "sg:person.01355345644.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355345644.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hentic", 
        "givenName": "Olivia", 
        "id": "sg:person.0736275266.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736275266.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neuzillet", 
        "givenName": "Cindy", 
        "id": "sg:person.0766573165.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766573165.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology Unit, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Oncology Unit, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faivre", 
        "givenName": "Sandrine", 
        "id": "sg:person.01026352014.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026352014.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology Unit, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Oncology Unit, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raymond", 
        "givenName": "Eric", 
        "id": "sg:person.0722574726.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722574726.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruszniewski", 
        "givenName": "Philippe", 
        "id": "sg:person.0640551545.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640551545.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6690325", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033288252", 
          "https://doi.org/10.1038/sj.bjc.6690325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1756-8722-4-29", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038626778", 
          "https://doi.org/10.1186/1756-8722-4-29"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-08-22", 
    "datePublishedReg": "2012-08-22", 
    "description": "There are numerous treatment options for patients with advanced digestive neuroendocrine tumours (NETs). Medical treatment includes systemic chemotherapies, targeted therapies, somatostatin analogs, liver-directed therapies such as (chemo)embolization or thermoablation, and peptide receptor radionuclide therapy. Cytotoxic chemotherapies can help control tumour progression in patients with non-resectable tumours and may improve symptoms by reducing tumour bulk. In addition, tumour response is usually greater than that obtained with targeted therapies. This should be taken into consideration in neoadjuvant strategies. Efficacy of temozolomide depends on the O6 methylguanine DNA methyl transferase status, and thus, this drug will likely have to be considered in the future in patients with a favourable enzyme profile. Because numerous treatment options are available for patients with advanced digestive NETs, and thanks to their long survival, successive drugs should be used. Careful attention should be paid to the adverse events in order to maintain the quality of life in these patients who have with a long life expectancy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11523-012-0228-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "advanced digestive neuroendocrine tumours", 
      "digestive neuroendocrine tumors", 
      "numerous treatment options", 
      "neuroendocrine tumors", 
      "treatment options", 
      "peptide receptor radionuclide therapy", 
      "liver-directed therapies", 
      "non-resectable tumors", 
      "receptor radionuclide therapy", 
      "new treatment options", 
      "efficacy of temozolomide", 
      "quality of life", 
      "longer life expectancy", 
      "neoadjuvant strategies", 
      "transferase status", 
      "systemic chemotherapy", 
      "cytotoxic chemotherapy", 
      "adverse events", 
      "somatostatin analogues", 
      "longer survival", 
      "tumor bulk", 
      "medical treatment", 
      "patients", 
      "radionuclide therapy", 
      "tumor progression", 
      "therapy", 
      "cytotoxic agents", 
      "tumors", 
      "life expectancy", 
      "chemotherapy", 
      "drugs", 
      "options", 
      "careful attention", 
      "enzyme profiles", 
      "temozolomide", 
      "symptoms", 
      "progression", 
      "thermoablation", 
      "efficacy", 
      "survival", 
      "treatment", 
      "expectancy", 
      "status", 
      "agents", 
      "response", 
      "life", 
      "events", 
      "profile", 
      "analogues", 
      "addition", 
      "quality", 
      "strategies", 
      "consideration", 
      "future", 
      "attention", 
      "order", 
      "thanks", 
      "bulk", 
      "O6 methylguanine DNA methyl transferase status", 
      "methylguanine DNA methyl transferase status", 
      "DNA methyl transferase status", 
      "methyl transferase status", 
      "favourable enzyme profile", 
      "successive drugs"
    ], 
    "name": "New treatment options with cytotoxic agents in neuroendocrine tumours", 
    "pagination": "169-172", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1047764482"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-012-0228-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22911013"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-012-0228-7", 
      "https://app.dimensions.ai/details/publication/pub.1047764482"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_573.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11523-012-0228-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0228-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0228-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0228-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0228-7'


 

This table displays all metadata directly associated to this object as RDF triples.

235 TRIPLES      22 PREDICATES      108 URIs      98 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-012-0228-7 schema:about N0275706aea2c42068debb053a6d816d1
2 N2757e71cb4bf4e47ab735da0e50cd136
3 N2a938d7b0b964534a850896c46f4914f
4 N2f7ec5264d074bd0a54ee9c4d79e3a67
5 N4f22f9e51b3e4710bb43bdcc693e8f97
6 N640a63b099804438ba7840cd74acd765
7 N695df8a3f0af474eae058ec55e677b8c
8 N9720581d147b4f64a118242056220743
9 N9f371d54b98d4111808b1a34cbd0eb4c
10 Na4b8c5bf39e24c229dd1e070c6d0bc8b
11 Nc56cef998d1e45438a37390043ad1daa
12 Nd469f8e35c7449618cde5ee55b2cdb38
13 Nd6bf16514592448aad6400971659538e
14 Nd83f60ccba324ebf979472949535d25b
15 Ne3db6081392c4d848c21a58103eb3d6d
16 Nf88561d6a24f44ba9a7cdb6dc17a0b7e
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N8ca7afbf42f445faaabcfe90b1074c71
20 schema:citation sg:pub.10.1038/sj.bjc.6690325
21 sg:pub.10.1186/1756-8722-4-29
22 schema:datePublished 2012-08-22
23 schema:datePublishedReg 2012-08-22
24 schema:description There are numerous treatment options for patients with advanced digestive neuroendocrine tumours (NETs). Medical treatment includes systemic chemotherapies, targeted therapies, somatostatin analogs, liver-directed therapies such as (chemo)embolization or thermoablation, and peptide receptor radionuclide therapy. Cytotoxic chemotherapies can help control tumour progression in patients with non-resectable tumours and may improve symptoms by reducing tumour bulk. In addition, tumour response is usually greater than that obtained with targeted therapies. This should be taken into consideration in neoadjuvant strategies. Efficacy of temozolomide depends on the O6 methylguanine DNA methyl transferase status, and thus, this drug will likely have to be considered in the future in patients with a favourable enzyme profile. Because numerous treatment options are available for patients with advanced digestive NETs, and thanks to their long survival, successive drugs should be used. Careful attention should be paid to the adverse events in order to maintain the quality of life in these patients who have with a long life expectancy.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf N3eda475db3cb43708187bcd170677eb1
29 N51cd6a295b3449a9ae44d40218e2c1bb
30 sg:journal.1036678
31 schema:keywords DNA methyl transferase status
32 O6 methylguanine DNA methyl transferase status
33 addition
34 advanced digestive neuroendocrine tumours
35 adverse events
36 agents
37 analogues
38 attention
39 bulk
40 careful attention
41 chemotherapy
42 consideration
43 cytotoxic agents
44 cytotoxic chemotherapy
45 digestive neuroendocrine tumors
46 drugs
47 efficacy
48 efficacy of temozolomide
49 enzyme profiles
50 events
51 expectancy
52 favourable enzyme profile
53 future
54 life
55 life expectancy
56 liver-directed therapies
57 longer life expectancy
58 longer survival
59 medical treatment
60 methyl transferase status
61 methylguanine DNA methyl transferase status
62 neoadjuvant strategies
63 neuroendocrine tumors
64 new treatment options
65 non-resectable tumors
66 numerous treatment options
67 options
68 order
69 patients
70 peptide receptor radionuclide therapy
71 profile
72 progression
73 quality
74 quality of life
75 radionuclide therapy
76 receptor radionuclide therapy
77 response
78 somatostatin analogues
79 status
80 strategies
81 successive drugs
82 survival
83 symptoms
84 systemic chemotherapy
85 temozolomide
86 thanks
87 therapy
88 thermoablation
89 transferase status
90 treatment
91 treatment options
92 tumor bulk
93 tumor progression
94 tumors
95 schema:name New treatment options with cytotoxic agents in neuroendocrine tumours
96 schema:pagination 169-172
97 schema:productId N356502439d114a9d9994576c2d5f6171
98 N604bc3fca6b246baa90a88cb0ba6c9dc
99 N67ee9ecacbc6402896f7bd43514147c4
100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047764482
101 https://doi.org/10.1007/s11523-012-0228-7
102 schema:sdDatePublished 2021-11-01T18:18
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher N044ce04aadeb4e55880155b0d4c5a9ee
105 schema:url https://doi.org/10.1007/s11523-012-0228-7
106 sgo:license sg:explorer/license/
107 sgo:sdDataset articles
108 rdf:type schema:ScholarlyArticle
109 N0275706aea2c42068debb053a6d816d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Treatment Outcome
111 rdf:type schema:DefinedTerm
112 N044ce04aadeb4e55880155b0d4c5a9ee schema:name Springer Nature - SN SciGraph project
113 rdf:type schema:Organization
114 N0e0d88420fc442c2944dc75b2d3d9ccf rdf:first sg:person.01026352014.76
115 rdf:rest N68d72eb979ec468ebd99af2e7dcd2ff5
116 N2757e71cb4bf4e47ab735da0e50cd136 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Carcinoid Tumor
118 rdf:type schema:DefinedTerm
119 N2a938d7b0b964534a850896c46f4914f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Neuroendocrine Tumors
121 rdf:type schema:DefinedTerm
122 N2f7ec5264d074bd0a54ee9c4d79e3a67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Medical Oncology
124 rdf:type schema:DefinedTerm
125 N356502439d114a9d9994576c2d5f6171 schema:name doi
126 schema:value 10.1007/s11523-012-0228-7
127 rdf:type schema:PropertyValue
128 N3eda475db3cb43708187bcd170677eb1 schema:issueNumber 3
129 rdf:type schema:PublicationIssue
130 N4f22f9e51b3e4710bb43bdcc693e8f97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Antibiotics, Antineoplastic
132 rdf:type schema:DefinedTerm
133 N51cd6a295b3449a9ae44d40218e2c1bb schema:volumeNumber 7
134 rdf:type schema:PublicationVolume
135 N604bc3fca6b246baa90a88cb0ba6c9dc schema:name pubmed_id
136 schema:value 22911013
137 rdf:type schema:PropertyValue
138 N640a63b099804438ba7840cd74acd765 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name DNA Modification Methylases
140 rdf:type schema:DefinedTerm
141 N6567bdfa93274e1b9267d4a450e87461 rdf:first sg:person.0640551545.21
142 rdf:rest rdf:nil
143 N67ee9ecacbc6402896f7bd43514147c4 schema:name dimensions_id
144 schema:value pub.1047764482
145 rdf:type schema:PropertyValue
146 N68d72eb979ec468ebd99af2e7dcd2ff5 rdf:first sg:person.0722574726.55
147 rdf:rest N6567bdfa93274e1b9267d4a450e87461
148 N695df8a3f0af474eae058ec55e677b8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Quality of Life
150 rdf:type schema:DefinedTerm
151 N8ca7afbf42f445faaabcfe90b1074c71 rdf:first sg:person.01355345644.55
152 rdf:rest Na44757973f864e5eae78c263db483e82
153 N9720581d147b4f64a118242056220743 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Temozolomide
155 rdf:type schema:DefinedTerm
156 N9f371d54b98d4111808b1a34cbd0eb4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name DNA Repair Enzymes
158 rdf:type schema:DefinedTerm
159 Na44757973f864e5eae78c263db483e82 rdf:first sg:person.0736275266.26
160 rdf:rest Ne081dd6d54074fae92433833486da564
161 Na4b8c5bf39e24c229dd1e070c6d0bc8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Antineoplastic Agents, Alkylating
163 rdf:type schema:DefinedTerm
164 Nc56cef998d1e45438a37390043ad1daa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Clinical Trials as Topic
166 rdf:type schema:DefinedTerm
167 Nd469f8e35c7449618cde5ee55b2cdb38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Humans
169 rdf:type schema:DefinedTerm
170 Nd6bf16514592448aad6400971659538e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Dacarbazine
172 rdf:type schema:DefinedTerm
173 Nd83f60ccba324ebf979472949535d25b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Cytotoxins
175 rdf:type schema:DefinedTerm
176 Ne081dd6d54074fae92433833486da564 rdf:first sg:person.0766573165.15
177 rdf:rest N0e0d88420fc442c2944dc75b2d3d9ccf
178 Ne3db6081392c4d848c21a58103eb3d6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Streptozocin
180 rdf:type schema:DefinedTerm
181 Nf88561d6a24f44ba9a7cdb6dc17a0b7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Tumor Suppressor Proteins
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
188 schema:name Oncology and Carcinogenesis
189 rdf:type schema:DefinedTerm
190 sg:journal.1036678 schema:issn 1776-2596
191 1776-260X
192 schema:name Targeted Oncology
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01026352014.76 schema:affiliation grid-institutes:grid.411599.1
196 schema:familyName Faivre
197 schema:givenName Sandrine
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026352014.76
199 rdf:type schema:Person
200 sg:person.01355345644.55 schema:affiliation grid-institutes:grid.411599.1
201 schema:familyName Hammel
202 schema:givenName Pascal
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355345644.55
204 rdf:type schema:Person
205 sg:person.0640551545.21 schema:affiliation grid-institutes:grid.411599.1
206 schema:familyName Ruszniewski
207 schema:givenName Philippe
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640551545.21
209 rdf:type schema:Person
210 sg:person.0722574726.55 schema:affiliation grid-institutes:grid.411599.1
211 schema:familyName Raymond
212 schema:givenName Eric
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722574726.55
214 rdf:type schema:Person
215 sg:person.0736275266.26 schema:affiliation grid-institutes:grid.411599.1
216 schema:familyName Hentic
217 schema:givenName Olivia
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736275266.26
219 rdf:type schema:Person
220 sg:person.0766573165.15 schema:affiliation grid-institutes:grid.411599.1
221 schema:familyName Neuzillet
222 schema:givenName Cindy
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766573165.15
224 rdf:type schema:Person
225 sg:pub.10.1038/sj.bjc.6690325 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033288252
226 https://doi.org/10.1038/sj.bjc.6690325
227 rdf:type schema:CreativeWork
228 sg:pub.10.1186/1756-8722-4-29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038626778
229 https://doi.org/10.1186/1756-8722-4-29
230 rdf:type schema:CreativeWork
231 grid-institutes:grid.411599.1 schema:alternateName Oncology Unit, Hôpital Beaujon, AP-HP, Faculté Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France
232 Service de Gastroenterologie-Pancreatologie, Hôpital Beaujon, AP-HP, Faculté Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France
233 schema:name Oncology Unit, Hôpital Beaujon, AP-HP, Faculté Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France
234 Service de Gastroenterologie-Pancreatologie, Hôpital Beaujon, AP-HP, Faculté Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France
235 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...